
What You Should Know
- Greatly Health raised a $4 million seed round co-led by Pear VC and Commonweal Ventures to bring integrative oncology to a broader patient population.
- The company’s virtual model was originally developed and validated at Memorial Sloan Kettering Cancer Center (MSK).
- In clinical trials, the program demonstrated a 16% absolute improvement in overall survival at two years and a 69% reduction in hospitalizations.
- The platform provides live, expert-led group sessions in exercise, nutrition, yoga, and mindfulness, paired with personalized coaching and symptom tracking.
- Greatly aims to move integrative therapies from philanthropy-funded extras to a reimbursed component of standard cancer care.
While integrative therapies like nutrition and exercise are recommended in oncology guidelines, they remain inaccessible to the majority of U.S. patients treated outside of major academic institutions. Greatly Health, a new healthtech pioneer, has announced a $4 million seed investment to solve this “access gap” by scaling a virtual, whole-person care model. Founded by digital health executive Chip Stine alongside MSK leaders Dr. Jun Mao and Dr. Robert Daly, the company is building a new category of care that integrates supportive therapies directly into the standard treatment journey.
The company’s timing aligns with a broader industry shift toward functional and lifestyle medicine. In December, CMS announced the MAHA ELEVATE initiative to fund research into how lifestyle interventions can support Medicare beneficiaries with chronic diseases. Greatly Health is positioning itself to lead this transition, moving integrative oncology from an out-of-pocket luxury to a core, reimbursed clinical utility.
Clinical Validation: Outcomes Comparable to New Therapies
The defining differentiator for Greatly Health is its origin in randomized clinical trials at MSK. The model isn’t just about “wellness”; it delivers hard clinical results. By helping patients manage debilitating symptoms like fatigue, pain, and depression, the program ensures they can stay on their standard treatments and avoid acute care utilization.
The magnitude of improvement observed—including a 42% reduction in treatment disruptions—is, according to co-founder Dr. Robert Daly, comparable to the impact of recently approved pharmaceutical therapies. By reducing isolation through a community-based model where patients attend live group sessions together, the platform improves both mental health and adherence to life-saving oncology protocols.
A Strategic Path to Universal Reimbursement
Greatly Health is currently expanding its model through partnerships with health plans, oncology providers, and life sciences companies. The company is already supporting approximately 200 patients with metastatic breast cancer through a collaboration with a global life sciences firm and a patient advocacy group. These partnerships are the first step in a long-term strategy to establish integrative oncology as a standard, reimbursed part of the cancer care stack.
With the new funding, Greatly plans to enhance its virtual technology platform, expand its internal clinical team, and broaden its offering to include additional evidence-based therapies. As oncology spending in the U.S. exceeds $200 billion annually, Greatly’s ability to drive down total costs through a 69% reduction in hospitalizations makes it a compelling partner for value-based care organizations.
